HER-2 OVEREXPRESSION IN BREAST CANCER PATIENTS IN SOLCA-CUENCA. 2016-2019.

Authors

  • Laura Cristina Orbe Muñoz Licenciada en Laboratorio Clínico. Laboratorio SinaiLab. Cuenca – Azuay – Ecuador. https://orcid.org/0009-0008-6520-4801
  • Juan Carlos Pozo Palacios Médico. Especialista de primer grado en Genética Clínica. Magister en Epidemiología. Carrera de Medicina. Facultad de Ciencias Médicas. Universidad de Cuenca. Cuenca – Azuay – Ecuador. https://orcid.org/0000-0002-2774-1787
  • Gabriele Davide Bigoni Ordóñez Licenciado en Laboratorio Clínico. Maestro en Ciencias Bioquímicas, campo de conocimiento Biología Molecular. Doctor en Ciencias Bioquímicas, campo de conocimiento Biología Molecular. Carrera de Laboratorio Clínico. Facultad de Ciencias Médicas. Universidad de Cuenca. Cuenca – Azuay – Ecuador https://orcid.org/0000-0003-2091-6107

DOI:

https://doi.org/10.18537/RFCM.41.02.03

Keywords:

breast neoplasms, risk factors, receptor ErbB-2

Abstract

Background: Breast cancer is the most frequent malignant neoplasm in the female population, constituting approximately 25% of all cancers in women around the world. This pathology presents a very heterogeneous etiology since several factors are involved. The HER-2 oncogene, encoding a transmembrane growth factor receptor, is overexpressed in 20 to 30% of breast cancer cases and is associated with an adverse prognosis of the disease due to its aggressive biological behavior.

Objective: To determine the frequency of HER-2 overexpression in breast cancer patients at the Solca Cancer Institute, Cuenca in the period 2016-2019.

Methodology: The present research was of cross-sectional analytical type, the sample consisted of all female patients with breast cancer, whose breast tissue samples were referred to the immunohistochemistry laboratory of Solca-Cuenca for HER-2 determination. Descriptive and analytical statistics using association tests were used for the analysis and interpretation of the results.

Results: 623 records of patients with breast cancer between 18 and 96 years of age, during 2016 and 2019 were included. 26.8% overexpressed HER-2. In HER-2 overexpression, no relationship was found with age, parity and family history, but there was a relationship with the stage of the disease and the expression of hormone receptors (estrogen and progesterone).

Key words: breast cancer, HER-2, risk factors.

Downloads

Download data is not yet available.

Downloads

Published

2023-07-25

Issue

Vol. 41 No. 2 (2023): Revista de la Facultad de Ciencias Médicas de la Universidad de Cuenca

Section

Original Article

License

Copyright (c) 2023 Laura Cristina Orbe Muñoz, Juan Carlos Pozo Palacios, Gabriele Davide Bigoni Ordóñez

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright © Autors.

You are free to:

Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Under the following conditions:

Attribution — You must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licenser endorses you or your use.
  NonCommercial  — You may not use the material for commercial purposes.
  ShareAlike  — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the licence permits.